$Sarepta Therap(SRPT.US) | ๐๐๐ซ๐๐ฉ๐ญ๐: H.C. Wainwright reiterates ๐๐๐ฅ๐ฅ, maintains ๐๐ ๐๐ญ $๐
Analyst sees rising efficacy risks from new Roche study, with limited upside and significant downside to core U.S. ELEVIDYS franchise.Source: Hardik Shah
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments